Abstract P6-13-01: Cost-effectiveness of ado-trastuzumab emtansine (T-DM1) versus trastuzumab (H) for the adjuvant treatment of patients with residual invasive HER2+ early breast cancer in the US
Abstract:Objectives: Ado-trastuzumab emtansine (T-DM1) is a HER2-targeted antibody drug conjugate (ADC) indicated for the adjuvant treatment of patients with HER2+ early breast cancer (eBC) who have residual invasive disease after neoadjuvant taxane and trastuzumab-based treatment. In a phase 3 clinical trial (KATHERINE, NCT01772472), T-DM1 demonstrated a statistically significant 50% reduction in the risk of invasive BC recurrence or death compared with trastuzumab (H) (HR= 0.5, 95% CI 0.39-0.64; p<0.001). This… Show more
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.